J Jaime Caro

Summary

Affiliation: United BioSource Corporation
Country: USA

Publications

  1. ncbi Unaltered ethical standards for individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event
    J Jaime Caro
    Department of Epidemiology, Biostatistics and Occupational Health, Division of General Internal Medicine, McGill University, Montreal
    J Clin Ethics 22:33-41. 2011
  2. ncbi Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences
    Krista F Huybrechts
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 12:16-9. 2009
  3. ncbi Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia
    K Jack Ishak
    United BioSource Corporation, Montreal, Quebec, Canada
    Clin Ther 30:1251-63. 2008
  4. ncbi The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke. Results from the Athens Stroke Registry
    Krista F Huybrechts
    United Biosource Corporation formerly Caro Research Institute, Lexington, MA 02420, USA
    Cerebrovasc Dis 26:381-7. 2008
  5. ncbi Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial
    Thitima Kongnakorn
    United BioSource Corporation, Lexington, MA 02420, USA
    Value Health 12:880-7. 2009
  6. ncbi Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
    Thitima Kongnakorn
    United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 26:17-24. 2010
  7. ncbi Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making
    J Jaime Caro
    Department of Epidemiology, Biostatistics and Occupational Health, McGill University
    Disaster Med Public Health Prep 5:S46-53. 2011
  8. ncbi Case-control studies in pharmacoeconomic research: an overview
    J Jaime Caro
    Department of Epidemiology, Biostatistics and Occupational Health, and Division of General Internal Medicine, McGill University, Montreal, Canada
    Pharmacoeconomics 27:627-34. 2009
  9. ncbi No head-to-head trial? simulate the missing arms
    J Jaime Caro
    Division of General Internal Medicine and Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    Pharmacoeconomics 28:957-67. 2010

Detail Information

Publications9

  1. ncbi Unaltered ethical standards for individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event
    J Jaime Caro
    Department of Epidemiology, Biostatistics and Occupational Health, Division of General Internal Medicine, McGill University, Montreal
    J Clin Ethics 22:33-41. 2011
    ..When resources become more available, patients with lower priority can be increasingly accommodated...
  2. ncbi Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences
    Krista F Huybrechts
    Caro Research Institute, Concord, MA 01742, USA
    Value Health 12:16-9. 2009
    ..This intervention was shown to be cost-effective in the United States. This paper presents the Canadian adaptation...
  3. ncbi Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia
    K Jack Ishak
    United BioSource Corporation, Montreal, Quebec, Canada
    Clin Ther 30:1251-63. 2008
    ....
  4. ncbi The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke. Results from the Athens Stroke Registry
    Krista F Huybrechts
    United Biosource Corporation formerly Caro Research Institute, Lexington, MA 02420, USA
    Cerebrovasc Dis 26:381-7. 2008
    ..The modified Rankin Scale (mRS) is gaining importance as a means to quantity disability following stroke, yet little is known about its usefulness as a determinant of the long-term outcome...
  5. ncbi Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial
    Thitima Kongnakorn
    United BioSource Corporation, Lexington, MA 02420, USA
    Value Health 12:880-7. 2009
    ..This study evaluated the economic implications of results obtained by the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial...
  6. ncbi Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
    Thitima Kongnakorn
    United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 26:17-24. 2010
    ..The economic implications of this new antibiotic, relative to imipenem for treatment of nosocomial pneumonia, were investigated...
  7. ncbi Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making
    J Jaime Caro
    Department of Epidemiology, Biostatistics and Occupational Health, McGill University
    Disaster Med Public Health Prep 5:S46-53. 2011
    ..Reassessment of patients' clinical status and priority for intervention also should be conducted with regularity...
  8. ncbi Case-control studies in pharmacoeconomic research: an overview
    J Jaime Caro
    Department of Epidemiology, Biostatistics and Occupational Health, and Division of General Internal Medicine, McGill University, Montreal, Canada
    Pharmacoeconomics 27:627-34. 2009
    ....
  9. ncbi No head-to-head trial? simulate the missing arms
    J Jaime Caro
    Division of General Internal Medicine and Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    Pharmacoeconomics 28:957-67. 2010
    ..An STC offers a way to derive comparative effectiveness in the absence of direct trial evidence and a platform to test design features that may help in planning future head-to-head studies...